Home Merck to Present New Data in Five Tumor Types from Studies Evaluating Pembrolizumab, the Companys Investigational Anti-PD-1 Antibody, at ESMO 2014
 

Keywords :   


Merck to Present New Data in Five Tumor Types from Studies Evaluating Pembrolizumab, the Companys Investigational Anti-PD-1 Antibody, at ESMO 2014

2014-09-02 14:30:00| Merck.com - Corporate News

Dateline City: WHITEHOUSE STATION, N.J. First Presentation of Findings in Gastric and Bladder (Urothelial Tract) Cancers WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of data from ongoing clinical trials evaluating the anti-tumor activity of pembrolizumab, the companys investigational anti-PD-1 antibody, at the European Society of Medical Oncology (ESMO) 2014 in Madrid, Spain, September 26 30. Language: English Contact: MerckMedia Contacts:Ian McConnell, 908-423-3046Claire Mulhearn, 908-423-7425Investor Contacts:Joseph Romanelli, 908-423-5185Justin Holko 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: data present types studies

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
22.11SHIMANO BT Master 11AP)
22.11
22.11
22.11GOLDWIN
22.11Qi10 TOUR 5W WF
22.11
22.11GX HR
22.11 GEORGIA
More »